News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors
Photo taken from genengnews.com
Aug 6, 2024, 11:41

Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors

Norbert Kraut,Global Head of Cancer Research at Boehringer Ingelheim, shared on X:

“Out now in Nature Cancer Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to MD Anderson Cancer Center, Tim Heffernan and team and congrats to the Boehringer Ingelheim KRAS team.”

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Authors: Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A. Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A. Machado, Thomas Madensky, Ethan D. Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M. Molkentine, Philipp A. Jaeger, David H. Peng, Robyn L. Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P. Vellano, Mark Petronczki, Norbert Kraut, Timothy P. Heffernan, Joseph R. Marszalek, Mark Pearson, Irene C. Waizenegger and Marco H. Hofmann.

Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors

Source: Norbert Kraut/X

Alexey Sorokin Annette A. Machado Astrid Jeschko Boehringer Ingelheim cancer Christoph Albrecht Christopher A. Bristow Christopher P. Vellano Daniel Gerlach David H. Peng Donat Alpar Ethan D. Marszalek Francesca Trapani Gabriella Melo-Zainzinger Hengyu Lyu Heribert Arnhof Irene C. Waizenegger Jessica M. Molkentine Joseph R. Marszalek Kaja Kostyrko Karin Bosch KRASG12C Marco H. Hofmann Mark Pearson Mark Petronczki MD Anderson Cancer Center Melanie Hinkel Michael Gmachl Mikhila Mahendra Nature Cancer Ningping Feng Norbert Kraut Oliver Bergner OncoDaily Oncology Philipp A. Jaeger relapsed mutant tumors Robyn L. Schenk Sabine Jurado Sandra Strauss Scott Kopetz Simone Lieb Sisi Gao Thomas Madensky Tim Heffernan Timothy P. Heffernan Venu Thatikonda
Special Coverage
Blog
Nov 14, 2024, 17:57
European Cancer Organisation's Memorandum of Understanding with UNFPA
Blog
Nov 14, 2024, 17:51
Research is for everyone. Every voice and experience matters - Young Lung Cancer Initiative
Blog
Nov 14, 2024, 17:48
Marco Donia: Pleased to be Co-chairing with Timothée Olivier in an educational session at ESMOImmuno24
Blog
Nov 14, 2024, 17:46
Dinesh Pendharkar: Continuing mission of Sickle cell disease and Cancer
Blog
Nov 14, 2024, 17:46
Abstracts submissions open for MASCC25
Blog
Nov 14, 2024, 17:42
Shahana Banerjee: Reimagining Healthcare with Sachin H. Jain
Blog
Nov 14, 2024, 17:32
Nandita Kotwani: KidsX collaboration with the CancerX Moonshot 2025 Accelerator program
Blog
Nov 14, 2024, 17:23
Douglas Flora: UK Markey Cancer Center Affiliate Network 2024 Cancer Care Conference
Blog
Nov 14, 2024, 17:19
Cate OReilly: Sally Werner on the transformative impact of supportive cancer care
Blog
Nov 14, 2024, 17:14
Petra Ibum Adjah: Men's Health Matter
Blog
Nov 14, 2024, 16:54
Roupen Odabashian: Looking for medical students or residents interested in conducting AI research in oncology
Blog
Nov 14, 2024, 16:48
ECO is pleased to announce the 16 selected abstracts for the European Cancer Summit 2024